DOMO (DOMO) PT Raised to $36 at Cowen Following 1Q Report
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
DOMO (DOMO) PT Raised to $30 at Credit Suisse
June 5, 2020 6:19 AM EDTCredit Suisse analyst Brad Zelnick raised the price target on DOMO (NASDAQ: DOMO) to $30.00 (from $14.00) while maintaining a Neutral rating.... More
DOMO (DOMO) PT Raised to $32 at UBS
June 5, 2020 5:53 AM EDTUBS analyst Jennifer Swanson Lowe raised the price target on DOMO (NASDAQ: DOMO) to $32.00 (from $17.00) while maintaining a Neutral rating.... More
DOMO (DOMO) PT Raised to $35 at JMP Securities
June 5, 2020 5:27 AM EDTJMP Securities analyst Patrick Walravens raised the price target on DOMO (NASDAQ: DOMO) to $35.00 (from $22.00) while maintaining a Market Outperform rating.... More
After-Hours Stock Movers 6/4: (QEP) (ADMS) (EXTR) HIGHER; (WORK) (MNLO) (COO) LOWER (more...)
June 4, 2020 5:26 PM EDTAfter-Hours Stock Movers:
QEP Resources, Inc. (NYSE: QEP) 26.9% HIGHER; announced today that it has entered into an amendment to its existing credit agreement with Wells Fargo Bank, National Association, and other lenders (the Credit Agreement).
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) 23% HIGHER; announced that its supplemental New Drug Application (sNDA) for GOCOVRI as a treatment for OFF episodes in Parkinsons disease (PD) patients receiving levodopa-based therapy has been accepted for review by the U.S. Food and Drug Administration... More
Domo, Inc. (DOMO) Tops Q1 EPS by 26c, Revenues Beat; Offers 2Q & FY21 EPS/Revenue Guidance Above Consensus
June 4, 2020 4:03 PM EDTDomo, Inc. (NASDAQ: DOMO) reported Q1 EPS of ($0.65), $0.26 better than the analyst estimate of ($0.91). Revenue for the quarter came in at $48.6 million versus the consensus estimate of $45.65 million.
Fiscal First Quarter Results
Total revenue was $48.6 million, an increase of 19% year over yearSubscription revenue was $42.4 million, an increase of 23% year over yearSubscription revenue represented 87% of total revenueBillings were $46.5 million or 13% year-over-year growthNet cash used in operating activities was $12.9 million, an... More